Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 11, 2004. The report is a notification of changes in directors' interests in the company's Ordinary Shares, specifically relating to the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a retirement fund.
Material Changes
The primary material change reported is a decrease in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan. As of October 7, 2004, the fund's holdings changed from 19,031,468 to 18,980,312 shares. This movement occurred at an average price of $43.73 per share.
Outlook, Risks, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future business performance. It notes that two directors, Dr. J.P. Garnier and Dr. T. Yamada, are potentially interested in the shares held in the fund in the same manner as other employees, as the Plan is a discretionary fund for current and former employees.
Key Facts for Investor Verification
- The reduction in ADR holdings (51,156 shares) was driven by a movement in the fund value, not necessarily a direct sale by directors.
- Directors Dr. J.P. Garnier and Dr. T. Yamada hold indirect interests through the discretionary retirement fund.
- The average transaction price for the fund movement was $43.73.
- This filing does not contain financial performance data for the company.